Evidence map›Paper›PMID 29791254›Full record

ArticleMolecular biology of the cell2018

A genome-wide microRNA screen identifies regulators of tetraploid cell proliferation.

Marc A Vittoria, Elizabeth M Shenk, Kevin P O'Rourke, Amanda F Bolgioni, Sanghee Lim, Victoria Kacprzak, Ryan J Quinton, Neil J Ganem

Abstract read
In one paragraph

Article in Molecular biology of the cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. CDK4/6 activity is required during GScience (New York, N.Y.) · 2024
    Article
  6. Whole-genome doubling in tissues and tumors.Trends in genetics : TIG · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marc A VittoriaDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Elizabeth M ShenkDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Kevin P O'RourkeWeill Cornell Medicine/Rockefeller University/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY 10065.
Amanda F BolgioniDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Sanghee LimDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Victoria KacprzakDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Ryan J QuintonDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Neil J GanemDepartment of Pharmacology and Experimental Therapeutics, University School of Medicine, Boston, MA 02118.
Boston University · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
Regulation of cell growth and proliferation by the Hippo pathwayR01GM117150 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NEIL J. GANEM · 2016 to 2026
$2.4M
Defining novel pathways that arrest genetically unstable tetraploid cellsR00CA154531 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GANEM, NEIL J. · 2013 to 2015
$723k
Defining novel pathways that arrest genetically unstable tetraploid cellsK99CA154531 · NCI · DANA-FARBER CANCER INST · PI GANEM, NEIL J. · 2011 to 2012
$300k
Defining Novel Mechanisms of Genome Instability in BRAF-mutant MelanomaF30CA228388 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VITTORIA, MARC ANTHONY · 2018 to 2022
$253k
Modeling metastatic colorectal cancer in vivoF30CA200110 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI O'ROURKE, KEVIN P. · 2016 to 2018
$138k
NCI NIH HHS F30 CA200110NCI NIH HHS F30 CA228388NCI NIH HHS K99 CA154531NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA154531NIGMS NIH HHS R01 GM117150NIGMS NIH HHS T32 GM008541
6 · The paper itself

Abstract

Tetraploid cells, which are most commonly generated by errors in cell division, are genomically unstable and have been shown to promote tumorigenesis. Recent genomic studies have estimated that ∼40% of all solid tumors have undergone a genome-doubling event during their evolution, suggesting a significant role for tetraploidy in driving the development of human cancers. To safeguard against the deleterious effects of tetraploidy, nontransformed cells that fail mitosis and become tetraploid activate both the Hippo and p53 tumor suppressor pathways to restrain further proliferation. Tetraploid cells must therefore overcome these antiproliferative barriers to ultimately drive tumor development. However, the genetic routes through which spontaneously arising tetraploid cells adapt to regain proliferative capacity remain poorly characterized. Here, we conducted a comprehensive gain-of-function genome-wide screen to identify microRNAs (miRNAs) that are sufficient to promote the proliferation of tetraploid cells. Our screen identified 23 miRNAs whose overexpression significantly promotes tetraploid proliferation. The vast majority of these miRNAs facilitate tetraploid growth by enhancing mitogenic signaling pathways (e.g., miR-191-3p); however, we also identified several miRNAs that impair the p53/p21 pathway (e.g., miR-523-3p), and a single miRNA (miR-24-3p) that potently inactivates the Hippo pathway via down-regulation of the tumor suppressor gene NF2. Collectively, our data reveal several avenues through which tetraploid cells may regain the proliferative capacity necessary to drive tumorigenesis.

Indexed as

Genetic TestingTetraploidyAdaptor Proteins, Signal TransducingCell ProliferationCyclin-Dependent Kinase Inhibitor p21Down-RegulationHumansMicroRNAsMitogensNeurofibromin 2PhosphoproteinsSignal TransductionTranscription FactorsTumor Suppressor Protein p53YAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCyclin-Dependent Kinase Inhibitor p21MicroRNAsMitogensNeurofibromin 2PhosphoproteinsTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53YAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID29791254
PMCPMC6080710
OpenAlexW2950896036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.